ESMO Guidelines Recommend Daraxonrasib for RAS G12-Mutated Metastatic PDAC

According to updates published by OncLive on August 19, 2026, the European Society for Medical Oncology has issued an express update to its clinical practice guidelines recommending daraxonrasib for the treatment of RAS G12–mutated metastatic pancreatic ductal adenocarcinoma.

The ESMO Guidelines Express Update provides oncologists with rapid protocol adjustments based on recent clinical trial data. Metastatic pancreatic ductal adenocarcinoma, commonly referred to as PDAC, remains one of the most difficult gastrointestinal cancers to treat successfully with standard systemic therapies.

RAS mutations, specifically the G12 variant, drive tumorigenesis in a significant subset of pancreatic cancer cases. Targeting these specific genetic alterations has historically presented major pharmacological challenges due to the biochemical structure of the RAS protein.

Daraxonrasib represents an emerging therapeutic class designed to inhibit these specific mutant pathways in patients with advanced disease. The inclusion of the agent in the updated ESMO guidelines marks a shift toward biomarker-driven treatment algorithms for metastatic pancreatic cancer.

Clinical oncologists treating patients with RAS G12–mutated metastatic PDAC will now integrate the ESMO recommendation into local hospital protocols and regional treatment pathways. Healthcare providers typically use these expert guidelines to determine optimal second-line or maintenance therapy options after initial chemotherapy regimens.

Additional safety data and long-term survival analyses from ongoing clinical investigations will continue to inform the precise positioning of daraxonrasib in future comprehensive guideline revisions. Researchers anticipate further data releases regarding combination strategies involving the targeted inhibitor.